Intracranial Response to Anti-Programmed Death 1 Therapy in a Patient with Metastatic Non-Small Cell Lung Cancer with Leptomeningeal Carcinomatosis

Suneel D Kamath; Priya U Kumthekar; Tim J Kruser; Nisha A Mohindra

doi:10.1634/theoncologist.2018-0022

Intracranial Response to Anti-Programmed Death 1 Therapy in a Patient with Metastatic Non-Small Cell Lung Cancer with Leptomeningeal Carcinomatosis

Oncologist. 2018 Dec;23(12):e159-e161. doi: 10.1634/theoncologist.2018-0022. Epub 2018 Aug 2.

Authors

Suneel D Kamath¹, Priya U Kumthekar², Tim J Kruser³, Nisha A Mohindra^{4

5}

Affiliations

¹ Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA suneel.kamath@northwestern.edu.
² Department of Neurology, Division of Neuro-Oncology, Northwestern University, Chicago, Illinois, USA.
³ Department of Radiation Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA.
⁴ Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
⁵ Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA.

Abstract

Central nervous system metastasis in non-small cell lung cancer remains a therapeutic challenge and confers a poor prognosis. Here we describe a patient with lung adenocarcinoma, parenchymal brain metastases, and leptomeningeal carcinomatosis who demonstrated a sustained response to programmed death 1 inhibition combined with stereotactic radiosurgery.

Publication types

Case Reports

MeSH terms

Aged
Brain Neoplasms / pathology
Brain Neoplasms / secondary*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / pathology
Female
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / pathology
Meningeal Carcinomatosis / drug therapy*
Meningeal Carcinomatosis / pathology
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
Treatment Outcome

Substances

Programmed Cell Death 1 Receptor